JP2010518009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518009A5 JP2010518009A5 JP2009548334A JP2009548334A JP2010518009A5 JP 2010518009 A5 JP2010518009 A5 JP 2010518009A5 JP 2009548334 A JP2009548334 A JP 2009548334A JP 2009548334 A JP2009548334 A JP 2009548334A JP 2010518009 A5 JP2010518009 A5 JP 2010518009A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- actriib
- sequence
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 166
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 166
- 102000004169 proteins and genes Human genes 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 101
- 150000001413 amino acids Chemical class 0.000 claims description 87
- 108020001507 fusion proteins Proteins 0.000 claims description 75
- 102000037865 fusion proteins Human genes 0.000 claims description 75
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 42
- 230000011664 signaling Effects 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 20
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 20
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 20
- 201000006938 muscular dystrophy Diseases 0.000 claims description 20
- 108010059616 Activins Proteins 0.000 claims description 16
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 16
- 239000000488 activin Substances 0.000 claims description 16
- 210000003205 muscle Anatomy 0.000 claims description 15
- 108010056852 Myostatin Proteins 0.000 claims description 14
- 210000000577 adipose tissue Anatomy 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 238000000423 cell based assay Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 239000000710 homodimer Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 208000001022 morbid obesity Diseases 0.000 claims description 8
- 238000011275 oncology therapy Methods 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 230000037257 muscle growth Effects 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000001076 sarcopenia Diseases 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- 230000004584 weight gain Effects 0.000 claims description 7
- 235000019786 weight gain Nutrition 0.000 claims description 7
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 208000012696 congenital leptin deficiency Diseases 0.000 claims description 4
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 4
- 208000020694 gallbladder disease Diseases 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 230000020763 muscle atrophy Effects 0.000 claims description 4
- 201000000585 muscular atrophy Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- -1 Q53 Chemical compound 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 38
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89930407P | 2007-02-02 | 2007-02-02 | |
| US60/899,304 | 2007-02-02 | ||
| US92708807P | 2007-05-01 | 2007-05-01 | |
| US60/927,088 | 2007-05-01 | ||
| US93188007P | 2007-05-25 | 2007-05-25 | |
| US60/931,880 | 2007-05-25 | ||
| PCT/US2008/001506 WO2008097541A2 (en) | 2007-02-02 | 2008-02-04 | Variants derived from actriib and uses therefor |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013055112A Division JP5876847B2 (ja) | 2007-02-02 | 2013-03-18 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2014032768A Division JP2014098028A (ja) | 2007-02-02 | 2014-02-24 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518009A JP2010518009A (ja) | 2010-05-27 |
| JP2010518009A5 true JP2010518009A5 (enExample) | 2011-03-24 |
| JP5554067B2 JP5554067B2 (ja) | 2014-07-23 |
Family
ID=39682306
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548334A Active JP5554067B2 (ja) | 2007-02-02 | 2008-02-04 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2013055112A Active JP5876847B2 (ja) | 2007-02-02 | 2013-03-18 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2014032768A Withdrawn JP2014098028A (ja) | 2007-02-02 | 2014-02-24 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2016087844A Active JP6317779B2 (ja) | 2007-02-02 | 2016-04-26 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2018067000A Active JP6662939B2 (ja) | 2007-02-02 | 2018-03-30 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2020022122A Withdrawn JP2020072750A (ja) | 2007-02-02 | 2020-02-13 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2021201830A Pending JP2022044589A (ja) | 2007-02-02 | 2021-12-13 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013055112A Active JP5876847B2 (ja) | 2007-02-02 | 2013-03-18 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2014032768A Withdrawn JP2014098028A (ja) | 2007-02-02 | 2014-02-24 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2016087844A Active JP6317779B2 (ja) | 2007-02-02 | 2016-04-26 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2018067000A Active JP6662939B2 (ja) | 2007-02-02 | 2018-03-30 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2020022122A Withdrawn JP2020072750A (ja) | 2007-02-02 | 2020-02-13 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
| JP2021201830A Pending JP2022044589A (ja) | 2007-02-02 | 2021-12-13 | ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US7842663B2 (enExample) |
| EP (6) | EP2607379B1 (enExample) |
| JP (7) | JP5554067B2 (enExample) |
| KR (5) | KR101669278B1 (enExample) |
| CN (5) | CN105884880B (enExample) |
| AR (1) | AR065169A1 (enExample) |
| AU (5) | AU2008214375B2 (enExample) |
| BR (1) | BRPI0808164B8 (enExample) |
| CA (2) | CA3038197A1 (enExample) |
| CY (1) | CY1115489T1 (enExample) |
| DK (1) | DK2607379T3 (enExample) |
| EA (3) | EA025891B1 (enExample) |
| ES (4) | ES2796347T3 (enExample) |
| HR (1) | HRP20140731T1 (enExample) |
| IL (6) | IL200171A (enExample) |
| ME (1) | ME02234B (enExample) |
| MX (5) | MX378700B (enExample) |
| NO (1) | NO3053933T3 (enExample) |
| PL (2) | PL3053933T3 (enExample) |
| PT (1) | PT2607379E (enExample) |
| RS (1) | RS53455B (enExample) |
| SI (1) | SI2607379T1 (enExample) |
| TW (9) | TW201627320A (enExample) |
| WO (1) | WO2008097541A2 (enExample) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| US9610327B2 (en) * | 2007-03-06 | 2017-04-04 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| CA2699936A1 (en) * | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| KR20110031951A (ko) | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2015202035B2 (en) * | 2008-08-14 | 2017-03-23 | Acceleron Pharma Inc. | Use of GDF traps to increase red blood cell levels |
| PE20150680A1 (es) | 2008-11-26 | 2015-05-16 | Amgen Inc | Variantes de polipeptidos receptores de activina iib y aplicaciones de estos |
| AU2010204985A1 (en) * | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| ES2655877T3 (es) * | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) * | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| KR102170682B1 (ko) * | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| AU2015203400A1 (en) * | 2009-08-13 | 2015-07-16 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| EP3202459B1 (en) | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| EP3260130B1 (en) * | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| ES2658292T3 (es) * | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| JP6472999B2 (ja) * | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | 代謝障害を治療するための方法 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| DK3520805T3 (da) | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| JP6401172B2 (ja) | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| CA2889209C (en) | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| KR20150136061A (ko) | 2013-02-01 | 2015-12-04 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | 대상에 항-액티빈-a 화합물의 투여 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| CN105683366B (zh) | 2013-08-23 | 2020-11-06 | 住友化学株式会社 | 用于制备视网膜组织和视网膜相关细胞的方法 |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| EP3131931B1 (en) | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| MX2017007519A (es) * | 2014-12-08 | 2017-08-22 | Novartis Ag | Antagonistas de miostatina o activina para el tratamiento de sarcopenia. |
| WO2016128523A1 (en) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| EA039118B1 (ru) * | 2015-04-01 | 2021-12-07 | Ридженерон Фармасьютикалз, Инк. | Способ лечения прогрессирующей оссифицирующей фибродисплазии |
| EP3280435B1 (en) * | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| JP2018530560A (ja) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス， インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| JP7072507B2 (ja) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| WO2017145166A1 (en) | 2016-02-25 | 2017-08-31 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Composition and method for treating amyotrophic lateral sclerosis |
| CA3015277A1 (en) | 2016-03-10 | 2017-09-14 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| WO2018067740A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma, Inc. | Compositions and method for treating kidney disease |
| AU2017338916B2 (en) * | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2018144542A1 (en) * | 2017-02-01 | 2018-08-09 | Acceleron Pharma Inc. | TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
| CN107011430B (zh) * | 2017-04-07 | 2020-09-01 | 哈尔滨医科大学 | 一种具有生物学活性的截短的生长分化因子11及其制备方法 |
| WO2018231905A1 (en) | 2017-06-14 | 2018-12-20 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| RU2683277C1 (ru) * | 2018-03-02 | 2019-03-27 | Наталья Константиновна Осина | Способ использования хондральных клеток для скринирования веществ, обладающих противовоспалительной активностью |
| AU2019262139A1 (en) | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Multispecific binders of TGFβ-superfamily ligands and uses thereof |
| IL278546B2 (en) | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| AU2020334924A1 (en) * | 2019-08-22 | 2022-04-07 | The Regents Of The University Of California | UBE3A for the treatment of Angelman syndrome |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| IL294611B1 (en) | 2020-01-08 | 2026-05-01 | Regeneron Pharma | Treatment of fibrodysplasia ossificans progressive |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| CA3177632A1 (en) | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| KR102680764B1 (ko) * | 2021-08-03 | 2024-07-04 | 주식회사 와이뮨 | Acvr2b를 표적으로 하는 퇴행성 관절염 치료 또는 진단용 조성물 |
| US20250041385A1 (en) | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
| EP4469489A4 (en) | 2022-01-28 | 2026-04-08 | 35Pharma Inc | Type IIB Variants of the Activin Receptor and Their Uses |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| US20260092096A1 (en) | 2024-05-14 | 2026-04-02 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| WO2026080757A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | Activin receptor type ii a/b (actriia/b) antibodies |
| WO2026102148A1 (en) | 2024-11-07 | 2026-05-15 | Diagonal Therapeutics Inc. | Alk1 / bmprii bispecific antibodies for treatment of ocular diseases |
Family Cites Families (224)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| EP0169016B2 (en) | 1984-07-16 | 2004-04-28 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
| JPH0637520B2 (ja) | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5182375A (en) | 1987-08-28 | 1993-01-26 | The Salk Institute For Biological Studies | DNA encoding follistatin |
| EP0548276A4 (en) | 1990-09-13 | 1993-12-29 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| AU654724B2 (en) | 1991-05-10 | 1994-11-17 | Salk Institute For Biological Studies, The | Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily |
| CA2108770C (en) | 1991-06-25 | 2007-04-03 | John M. Wozney | Bmp-9 compositions |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| EP0661993B1 (en) | 1992-09-16 | 1997-05-07 | Genentech, Inc. | Protection against liver damage by hgf |
| US6692925B1 (en) * | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| CA2153652A1 (en) * | 1993-01-12 | 1994-07-21 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| ATE265529T1 (de) | 1993-05-12 | 2004-05-15 | Inst Genetics Llc | Bmp-10 zusammensetzungen |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5831050A (en) | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
| US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| DE69434934D1 (de) | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5658876A (en) * | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
| GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6132988A (en) | 1995-10-27 | 2000-10-17 | Takeda Chemical Industries, Ltd. | DNA encoding a neuronal cell-specific receptor protein |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6004780A (en) * | 1996-03-26 | 1999-12-21 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| US20050244867A1 (en) * | 1996-03-26 | 2005-11-03 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| CA2268001A1 (en) | 1996-10-25 | 1998-05-07 | G.D. Searle & Co. | Circularly permuted erythropoietin receptor agonists |
| US6605699B1 (en) * | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| US6034062A (en) | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| ES2320603T3 (es) | 1997-07-30 | 2009-05-25 | Emory University | Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos. |
| WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| AU8921698A (en) * | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
| AU750453B2 (en) | 1997-10-03 | 2002-07-18 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| US6696411B1 (en) * | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| WO2000015224A1 (en) | 1998-09-17 | 2000-03-23 | Eli Lilly And Company | Protein formulations |
| JP2002526073A (ja) * | 1998-09-22 | 2002-08-20 | 龍 余 | 新規のヒト生長分化因子のコード配列、そのｄｎａ配列によりコードされるポリペプチド、およびこれらの製造方法。 |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
| US6238860B1 (en) | 1998-11-05 | 2001-05-29 | Dyax Corp. | Binding moieties for human parvovirus B19 |
| US6777205B1 (en) * | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CA2365449A1 (en) | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibitor of the growth of androgen-independent tumor |
| US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| WO2001009368A1 (en) | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| JP2003513681A (ja) * | 1999-11-12 | 2003-04-15 | マキシゲン・ホールディングス・リミテッド | インターフェロンガンマ・コンジュゲート |
| IL150198A0 (en) | 1999-12-15 | 2002-12-01 | Res Dev Foundation | Betaglycan as an inhibin receptor and uses thereof |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| MEP90708A (hr) | 2000-05-15 | 2011-12-20 | Nova farmaceutska smješa | |
| US6627424B1 (en) | 2000-05-26 | 2003-09-30 | Mj Bioworks, Inc. | Nucleic acid modifying enzymes |
| WO2001098478A2 (en) | 2000-06-22 | 2001-12-27 | Mcgill University | Clk-2, cex-7 and coq-4 genes, and uses thereof |
| EP1303605A2 (en) | 2000-07-19 | 2003-04-23 | Eli Lilly And Company | Nucleic acids, vectors, host cells, polypeptides, and uses thereof |
| US6632180B1 (en) | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
| DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| CN1474831A (zh) | 2000-11-20 | 2004-02-11 | ����ŵ˹������ѧ�йܻ� | 膜支架蛋白 |
| EP1370287A2 (en) | 2000-12-01 | 2003-12-17 | Wyeth | Method and composition for modulating bone growth |
| US20030082233A1 (en) | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
| AU3323002A (en) * | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US20040132675A1 (en) * | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
| US7294472B2 (en) | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
| US20040121008A1 (en) | 2001-03-16 | 2004-06-24 | Keiko Shiraishi | Process for producing sustained release preparation |
| PL403488A1 (pl) | 2001-05-24 | 2013-07-08 | Zymogenetics, Inc. | Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina |
| WO2002094864A2 (en) | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| KR100912852B1 (ko) | 2001-07-17 | 2009-08-18 | 데이진 가부시키가이샤 | ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는물질의 선택방법 및 약제 |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| HU229475B1 (en) | 2001-12-06 | 2014-01-28 | Fibrogen | Methods of increasing endogenous erythropoietin (epo) |
| US20060234918A1 (en) | 2001-12-19 | 2006-10-19 | Voyager Pharmaceutical Corporation | Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| MXPA04007583A (es) | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
| US20030219846A1 (en) | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| AU2003232485A1 (en) | 2002-04-18 | 2003-10-27 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| AU2003261246A1 (en) | 2002-08-16 | 2004-03-03 | Wyeth | Bmp-2 estrogen responsive element and methods of using the same |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2002953327A0 (en) | 2002-12-12 | 2003-01-09 | Monash University | Methods of diagnosing prognosing and treating activin associated diseases and conditions |
| BRPI0407276A (pt) | 2003-02-07 | 2006-01-31 | Prometic Biosciences Inc | ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese |
| US20070155661A1 (en) * | 2003-02-14 | 2007-07-05 | The Board Of Trustees Of The Leland Standord Junior University | Methods and compositions for modulating the development of stem cells |
| WO2004082710A1 (en) | 2003-03-21 | 2004-09-30 | Lorantis Limited | Treatment of allergic diseases using a modulator of the notch signaling pathway |
| US20040197828A1 (en) | 2003-03-26 | 2004-10-07 | Gaddy Dana P. | Method for diagnosis and treatment of bone turnover |
| WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| CN1835974A (zh) | 2003-06-16 | 2006-09-20 | 细胞技术研究与发展公司 | 对硬化素特异的抗体和用于增加骨矿化的方法 |
| WO2005009460A2 (en) | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| WO2005032578A1 (en) | 2003-10-06 | 2005-04-14 | Monash University | Therapeutic method |
| US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| US20050197292A1 (en) * | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| JP2007530055A (ja) | 2004-03-26 | 2007-11-01 | アクセルロン ファーマ インコーポレーテッド | Ｂｍｐ−３プロペプチドおよび関連する方法 |
| CA2561809A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| WO2005113590A2 (en) | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
| EP1771557B1 (en) | 2004-06-24 | 2014-12-31 | Acceleron Pharma Inc. | GDF3 Propeptides and Related Methods |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| CN101098854B (zh) * | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| JP2008508878A (ja) | 2004-08-05 | 2008-03-27 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 細胞の発生および機能に対する効果を有する分子 |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| EP1804824B1 (en) | 2004-09-29 | 2017-01-04 | Icahn School of Medicine at Mount Sinai | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EP2954903A1 (en) | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| JPWO2006115274A1 (ja) | 2005-04-26 | 2008-12-18 | 味の素株式会社 | 骨髄赤血球前駆細胞分化促進剤 |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| JP2007099764A (ja) | 2005-09-09 | 2007-04-19 | Ajinomoto Co Inc | 血糖低下剤 |
| BRPI0616589A2 (pt) | 2005-09-28 | 2011-06-28 | Zymogenetics Inc | polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| WO2007071023A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2634940A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| WO2007076127A2 (en) | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
| JP4925364B2 (ja) | 2006-01-20 | 2012-04-25 | ベックマン コールター， インコーポレイテッド | 鉄欠乏を検出する方法 |
| US7820721B2 (en) | 2006-01-25 | 2010-10-26 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| KR20080098615A (ko) | 2006-02-28 | 2008-11-11 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
| CA2650131A1 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| AU2007249827A1 (en) | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| MX2009000722A (es) | 2006-07-21 | 2009-06-11 | Lyne Lab | Composiciones liquidas de acetato de calcio. |
| GB0615129D0 (en) | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
| WO2008073292A2 (en) | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| CA2672581A1 (en) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) * | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US9610327B2 (en) | 2007-03-06 | 2017-04-04 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| EP2150560A1 (en) * | 2007-06-01 | 2010-02-10 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| AU2008285289A1 (en) | 2007-08-03 | 2009-02-12 | Biomarin Iga Limited | Drug combinations for the treatment of Duchenne muscular dystrophy |
| GB0715938D0 (en) | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| WO2009025651A1 (en) | 2007-08-17 | 2009-02-26 | University Of Maine System Board Of Trustees | Biologically active peptide and method of using the same |
| US20100279409A1 (en) | 2007-09-13 | 2010-11-04 | Neil Robson | Method for modifying celluar immune resonse by modulating activin activity |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| CN101925611A (zh) | 2007-11-21 | 2010-12-22 | 安姆根有限公司 | Wise结合剂和表位 |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| WO2009137613A2 (en) | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| KR20110031951A (ko) | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| EP2315602A4 (en) | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US20110293526A1 (en) | 2008-11-20 | 2011-12-01 | University Of Southern California | Compositions and methods to modulate hair growth |
| PE20150680A1 (es) | 2008-11-26 | 2015-05-16 | Amgen Inc | Variantes de polipeptidos receptores de activina iib y aplicaciones de estos |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| US8110355B2 (en) | 2009-02-20 | 2012-02-07 | GenRemedy, LLC | Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis |
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| KR102170682B1 (ko) | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| EP3202459B1 (en) | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| EP3260130B1 (en) | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| JP6472999B2 (ja) | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | 代謝障害を治療するための方法 |
| DK3520805T3 (da) | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| WO2013063536A1 (en) | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| CA2853187A1 (en) | 2011-10-28 | 2013-05-02 | Paranta Biosciences Limited | A method of treating mucus hypersecretion |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| ES2663993T3 (es) | 2012-05-17 | 2018-04-17 | Paranta Biosciences Limited | Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido |
| US9663569B2 (en) | 2012-06-14 | 2017-05-30 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases |
| CA2874117C (en) | 2012-07-02 | 2021-10-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia |
| CA2889209C (en) | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| JP6401172B2 (ja) | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| WO2014064292A1 (en) | 2012-10-26 | 2014-05-01 | Universite Pierre Et Marie Curie (Paris 6) | A method for preventing or treating atrial fibrillation |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| WO2014093531A1 (en) | 2012-12-11 | 2014-06-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Modulation of myofiber repair by anti-myostatin in strategies with stem cells |
| CA2898121A1 (en) | 2013-01-25 | 2014-07-31 | Shire Human Genetic Therapies, Inc. | Follistatin in treating duchenne muscular dystrophy |
| US20140220033A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| WO2014152940A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| WO2014187807A1 (en) | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Follistatin derivatives |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015022658A2 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
| WO2015089575A1 (en) | 2013-12-16 | 2015-06-25 | Paranta Biosciences Limited | Method of diagnosis and treatment |
| WO2015108972A1 (en) | 2014-01-14 | 2015-07-23 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
| EP3100056A2 (en) | 2014-01-27 | 2016-12-07 | Novartis AG | Biomarkers predictive of muscle atrophy, method and use |
| WO2015152183A1 (ja) | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| EP3131931B1 (en) | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| TW201622746A (zh) | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| PE20170471A1 (es) | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
-
2008
- 2008-02-01 TW TW105102655A patent/TW201627320A/zh unknown
- 2008-02-01 TW TW103100799A patent/TWI548647B/zh active
- 2008-02-01 TW TW108124322A patent/TW201940502A/zh unknown
- 2008-02-01 TW TW109106066A patent/TW202021980A/zh unknown
- 2008-02-01 TW TW109134482A patent/TW202104248A/zh unknown
- 2008-02-01 TW TW107139774A patent/TW201907946A/zh unknown
- 2008-02-01 TW TW097103897A patent/TWI432449B/zh active
- 2008-02-01 TW TW110148946A patent/TWI782836B/zh active
- 2008-02-01 TW TW106133938A patent/TW201803890A/zh unknown
- 2008-02-04 ES ES17185627T patent/ES2796347T3/es active Active
- 2008-02-04 BR BRPI0808164A patent/BRPI0808164B8/pt active IP Right Grant
- 2008-02-04 WO PCT/US2008/001506 patent/WO2008097541A2/en not_active Ceased
- 2008-02-04 PL PL15199387T patent/PL3053933T3/pl unknown
- 2008-02-04 ES ES14175663.5T patent/ES2587934T3/es active Active
- 2008-02-04 NO NO15199387A patent/NO3053933T3/no unknown
- 2008-02-04 CN CN201610237097.7A patent/CN105884880B/zh active Active
- 2008-02-04 PL PL13157694T patent/PL2607379T3/pl unknown
- 2008-02-04 MX MX2019004066A patent/MX378700B/es unknown
- 2008-02-04 US US12/012,652 patent/US7842663B2/en active Active
- 2008-02-04 ES ES15199387.0T patent/ES2652318T3/es active Active
- 2008-02-04 AR ARP080100464A patent/AR065169A1/es active IP Right Grant
- 2008-02-04 ES ES13157694.4T patent/ES2488854T3/es active Active
- 2008-02-04 JP JP2009548334A patent/JP5554067B2/ja active Active
- 2008-02-04 CA CA3038197A patent/CA3038197A1/en active Pending
- 2008-02-04 SI SI200831230T patent/SI2607379T1/sl unknown
- 2008-02-04 ME MEP-2016-201A patent/ME02234B/me unknown
- 2008-02-04 EA EA201300713A patent/EA025891B1/ru unknown
- 2008-02-04 EP EP13157694.4A patent/EP2607379B1/en active Active
- 2008-02-04 MX MX2009008154A patent/MX2009008154A/es active IP Right Grant
- 2008-02-04 CN CN200880011247.6A patent/CN101679505B/zh active Active
- 2008-02-04 MX MX2014013208A patent/MX350324B/es unknown
- 2008-02-04 CN CN201610237110.9A patent/CN105906708A/zh active Pending
- 2008-02-04 EA EA201691260A patent/EA033623B1/ru unknown
- 2008-02-04 EA EA200970729A patent/EA018868B1/ru unknown
- 2008-02-04 EP EP17185627.1A patent/EP3293198B1/en active Active
- 2008-02-04 MX MX2017006700A patent/MX363943B/es unknown
- 2008-02-04 CA CA2677160A patent/CA2677160C/en active Active
- 2008-02-04 EP EP08725179.9A patent/EP2125884B1/en active Active
- 2008-02-04 AU AU2008214375A patent/AU2008214375B2/en active Active
- 2008-02-04 RS RS20140403A patent/RS53455B/sr unknown
- 2008-02-04 EP EP20157475.3A patent/EP3708578A1/en not_active Withdrawn
- 2008-02-04 KR KR1020097016779A patent/KR101669278B1/ko active Active
- 2008-02-04 EP EP14175663.5A patent/EP2805967B1/en active Active
- 2008-02-04 KR KR1020217034038A patent/KR102382781B1/ko active Active
- 2008-02-04 EP EP15199387.0A patent/EP3053933B1/en active Active
- 2008-02-04 KR KR1020167028978A patent/KR101801506B1/ko active Active
- 2008-02-04 CN CN201610236454.8A patent/CN105924517B/zh active Active
- 2008-02-04 KR KR1020197026911A patent/KR102317987B1/ko active Active
- 2008-02-04 CN CN201610236418.1A patent/CN105906707B/zh active Active
- 2008-02-04 DK DK13157694.4T patent/DK2607379T3/da active
- 2008-02-04 PT PT131576944T patent/PT2607379E/pt unknown
- 2008-02-04 KR KR1020177033274A patent/KR102072897B1/ko active Active
-
2009
- 2009-07-30 IL IL200171A patent/IL200171A/en active IP Right Grant
- 2009-07-30 MX MX2020014234A patent/MX2020014234A/es unknown
-
2010
- 2010-09-29 US US12/893,976 patent/US8343933B2/en active Active
-
2012
- 2012-12-28 US US13/730,418 patent/US9399669B2/en active Active
-
2013
- 2013-03-04 IL IL225045A patent/IL225045A/en active IP Right Grant
- 2013-03-18 JP JP2013055112A patent/JP5876847B2/ja active Active
-
2014
- 2014-02-24 JP JP2014032768A patent/JP2014098028A/ja not_active Withdrawn
- 2014-07-29 HR HRP20140731AT patent/HRP20140731T1/hr unknown
- 2014-08-14 CY CY20141100660T patent/CY1115489T1/el unknown
-
2015
- 2015-08-12 IL IL240522A patent/IL240522B/en active IP Right Grant
- 2015-08-12 IL IL240521A patent/IL240521A/en active IP Right Grant
-
2016
- 2016-04-26 JP JP2016087844A patent/JP6317779B2/ja active Active
- 2016-07-01 US US15/201,031 patent/US10259861B2/en active Active
- 2016-07-27 AU AU2016208313A patent/AU2016208313B2/en active Active
-
2018
- 2018-02-16 AU AU2018201131A patent/AU2018201131A1/en not_active Abandoned
- 2018-03-30 JP JP2018067000A patent/JP6662939B2/ja active Active
-
2019
- 2019-02-27 US US16/287,531 patent/US20200071381A1/en not_active Abandoned
- 2019-10-04 AU AU2019240707A patent/AU2019240707B2/en active Active
-
2020
- 2020-02-13 JP JP2020022122A patent/JP2020072750A/ja not_active Withdrawn
- 2020-06-23 IL IL275608A patent/IL275608B/en unknown
-
2021
- 2021-09-19 IL IL286494A patent/IL286494A/en unknown
- 2021-10-05 AU AU2021245102A patent/AU2021245102A1/en not_active Abandoned
- 2021-12-13 JP JP2021201830A patent/JP2022044589A/ja active Pending
-
2022
- 2022-01-19 US US17/578,792 patent/US20220281951A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008097541A4 (en) | Variants derived from actriib and uses therefor | |
| JP7474729B2 (ja) | 肺高血圧症を治療するための組成物および方法 | |
| JP2021511826A5 (enExample) | ||
| JP2011530599A5 (enExample) | ||
| JP7079301B2 (ja) | 安定性が増加されたグルカゴン誘導体 | |
| ES2280083T3 (es) | Composiciones de proteinas de fusion ob y metodos. | |
| RS61881B1 (sr) | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića | |
| JP2022177286A (ja) | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 | |
| KR20190071758A (ko) | 신규한 하이브리드 actriib 리간드 트랩 단백질을 사용한 근육 소모 및 골 질환의 치료 방법 | |
| JP2020521478A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2021522790A5 (enExample) | ||
| MA30440B1 (fr) | NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2). | |
| JP2019501141A (ja) | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート | |
| JP2008518026A5 (enExample) | ||
| US20240299493A1 (en) | Compositions and methods for treating pulmonary hypertension | |
| JPWO2020040245A5 (enExample) | ||
| CN115515618A (zh) | 用于治疗肾脏疾病或病症的单臂ActRIIA和ActRIIB异多聚体和方法 | |
| US20250281630A1 (en) | Pharmaceutical composition for cancer treatment and/or prevention | |
| EP2911661B1 (en) | Treatment of lung cancer using the smad3 inhibitor sis3 | |
| EP4274600A1 (en) | Compositions and methods for treating pulmonary hypertension | |
| UA122967C2 (uk) | Похідна глюкагону | |
| Kuzawińska et al. | Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment | |
| WO2004006898A3 (en) | Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease | |
| CN120305418A (zh) | 使用靶向her2的双特异性抗原结合构建体治疗胆道癌的方法 |